KIT and neoplasm: Sunitinib is a multitarget TKI against vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT that is effective in eliciting tumor response and disease stabilization in imatinib-resistant GISTs [9].